With a combined integrative and bioinformatics approach, we identified the dysregulation in the cell cycle pathway and predicted the activation of NEK2 and AURKA across breast cancer, colon cancer, LUAD, ovarian cancer, and UCEC. Here, NEK2 is linked to breast carcinoma.